Histamine antagonists promote cancer immunosurveillance

Peng Liu; Guido Kroemer; Oliver Kepp

doi:10.1080/2162402X.2023.2242211

Histamine antagonists promote cancer immunosurveillance

Oncoimmunology. 2023 Aug 5;12(1):2242211. doi: 10.1080/2162402X.2023.2242211. eCollection 2023.

Authors

Peng Liu^{1

2}, Guido Kroemer^{1

2

3}, Oliver Kepp^{1

2}

Affiliations

¹ Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris Saclay, Villejuif, France.
² Centre de Recherche des Cordeliers, Equipe Labellisée Par la Ligue Contre le Cancer, Université Paris Cité, Sorbonne Université, Inserm U1138, Institut Universitaire de France, Paris, France.
³ Institut du Cancer Paris CARPEM, Department of Biology, APHP, Hôpital Européen Georges Pompidou, Paris, France.

Abstract

Recently, a cellular mini-immune system comprising infinitely expandable dendritic cells and T cells led to the discovery that histamine receptor H1 antagonists act on T cells to stimulate their proliferation and polarization toward a Th1/Tc1 phenotype and to increase their anticancer activity in the context of immunochemotherapy.

Keywords: cancer; cell death; immunotherapy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Histamine Antagonists*
Histamine H1 Antagonists
Humans
Monitoring, Immunologic
Neoplasms* / drug therapy
T-Lymphocytes

Substances

Histamine Antagonists
Histamine H1 Antagonists